brigatinib-resistant ALK mutants
Pathways in the brigatinib-resistant ALK mutants SuperPath
| # | Name | Source | Genes |
|---|---|---|---|
| 1 | brigatinib-resistant ALK mutants | Reactome | |
| 2 | Brigatinib Pathway, Pharmacokinetics/Pharmacodynamics | PharmGKB | |
| 3 | Paclitaxel Pathway, Pharmacokinetics | PharmGKB | |
| 4 | Furmonertinib Pathway, Pharmacokinetics | PharmGKB | |
| 5 | ASP-3026-resistant ALK mutants | Reactome | |
| 6 | crizotinib-resistant ALK mutants | Reactome | |
| 7 | Drug resistance of ALK mutants | Reactome | |
| 8 | lorlatinib-resistant ALK mutants | Reactome | |
| 9 | NVP-TAE684-resistant ALK mutants | Reactome | |
| 10 | alectinib-resistant ALK mutants | Reactome | |
| 11 | ceritinib-resistant ALK mutants | Reactome |
Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways
Disorders associated with brigatinib-resistant ALK mutants SuperPath
according to GeneCards Suite gene sharing
| # | Disorder | Type | Genes | Score |
|---|---|---|---|---|
| 1 | Neuroblastoma 3 | Enrichment | ALK | 4.13 |
| 2 | Alk-positive anaplastic large cell lymphoma | Enrichment | ALK | 4.13 |
| 3 | Alk-positive large b-cell lymphoma | Enrichment | ALK | 4.13 |
| 4 | Drug metabolism, altered, cyp2c8-related | Enrichment | CYP2C8 | 3.83 |
| 5 | Vitamin d-dependent rickets, type 3 | Enrichment | CYP3A4 | 3.83 |
| 6 | Inflammatory myofibroblastic tumor | Enrichment | ALK | 3.35 |
| 7 | Lung squamous cell carcinoma | Enrichment | ALK | 3.35 |
| 8 | Melanocytic nevus syndrome, congenital | Enrichment | ALK | 3.23 |
| 9 | Neuroblastoma | Enrichment | ALK | 3.23 |
| 10 | Rhabdomyosarcoma | Enrichment | ALK | 2.93 |
| 11 | Differentiated thyroid carcinoma | Enrichment | ALK | 2.67 |
| 12 | Lung cancer | Enrichment | ALK | 2.63 |
| 13 | Ovarian cancer | Enrichment | ALK | 2.13 |
| 14 | Inherited cancer-predisposing syndrome | Enrichment | ALK | 2.01 |
